Prognostic Factors in Patients with Locally Advanced Breast Cancer Treated by Neoadjuvant Chemotherapy

Min Jaegal; Shin Jae Kang; Young Jae Ryu; Jin Seong Cho; Min Ho Park; Jung Han Yoon

추천

검색

자료유형: 학술저널

저자정보: Min Jaegal Shin Jae Kang Young Jae Ryu Jin Seong Cho Min Ho Park Jung Han Yoon

저널정보: 한국유방암학회 Journal of Breast Disease Journal of Breast Disease 제7권 제1호

발행연도: 2019.1

수록면: 23 - 29 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Neoadjuvant chemotherapy (NAC) has become the standard treatment for patients with locally advanced breast cancer. The purpose of this study was to evaluate prognosis according to molecular subtype and clinicopathologic factors in patients with locally advanced breast cancer treated by NAC. Methods: We retrospectively analyzed the medical records of 91 patients with breast cancer who underwent NAC followed by surgery between January 2005 and January 2010. The patients were classified into four molecular subtype groups: luminal A, luminal B, HER2 enriched, and triple negative (TN). Results: Thirty-five (38%) patients had luminal A, 13 (14%) patients luminal B, 22 (24%) patients HER2 enriched and 21 (21%) patients TN breast cancer. Patients with TN breast cancer tended to be more than 50 years of age and to have a higher histologic grade. There were statistically significant differences according to ypN stage (ypN0 vs. ypN1–3; p=0.019, 5-year disease-free survival [DFS]; p=0.005, 5-year overall survival [OS]) and lymphovascular invasion (LVI) (p=0.003, 5-year DFS; p=0.006, 5-year OS) in the univariate analysis. In the multivariate analysis, LVI was a significant factor in 5-year DFS (odds ratio 2.145, 95% confidence interval 1.064–4.324, p=0.033). There was no significant difference among molecular subtypes in DFS (p=0.161) or OS (p=0.084). Conclusion: LVI was associated with prognosis in patients with locally advanced breast cancer treated by NAC and surgery. However, molecular subtype had no effect on 5-year DFS or OS.

참고문헌 (21)

참고문헌 신청

Kuerer HM / 1999 / Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy / J Clin Oncol 17:460~469

Charfare H / 2005 / Neoadjuvant chemotherapy in breast cancer / Br J Surg 92:14~23

Boughey JC / 2013 / Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial / JAMA 310:1455~1461

Von Minckwitz G / 2012 / Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes / J Clin Oncol 30:1796~1804

Denkert C / 2010 / Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer / J Clin Oncol 28:105~113

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!